Sarepta Therapeutics (SRPT) Posts Smaller Q1 Loss

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.56), $0.71 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $188.8 million versus the consensus estimate of $206.44 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
• Constellation Brands (STZ) Tops Q1 EPS by 18c